China's first homegrown surgical robot for cardiovascular interventions, the ETcath, has received market approval after eight years of development.

Developed by Beijing WeMed Medical Technology Co. Ltd., a Beijing-based medical equipment company, the ETcath boasts a 100% success rate across hundreds of clinical trials. The robot integrates cutting-edge international technology, with its standout feature being a force feedback system. This innovation allows the robot to detect resistance as subtle as 0.01 newtons, enabling precise control and minimizing risks like vascular damage during complex procedures.

The ETcath also promises to transform working conditions for interventional surgeons. Traditionally, these specialists wear heavy lead protective gear and operate in radiation-heavy environments. With the robot, doctors can perform surgeries remotely while dressed in regular clothing.

The market approval paves the way for the ETcath to be rolled out to medical institutions nationwide. Next, the company will conduct multi-center research and clinical application demonstrations across China to further showcase its capabilities.

Yang He, the company's CEO said that the ETcath's development was supported by Beijing's strong innovation ecosystem, which offers policies and resources assisting innovative teams and companies.